Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12 ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its target price decreased by analysts at The Goldman Sachs Group from $22.00 to ...

What Happened? Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after ...

Q4 2024 Earnings Call Transcript March 3, 2025 Fortrea Holdings Inc. misses on earnings expectations. Reported EPS is $0.18 ...

Clinical research company Fortrea Holdings (NASDAQ:FTRE) in Q4 CY2024, with sales falling 1.8% year on year to $697 million.

Fortrea (NASDAQ:FTRE – Free Report) had its target price lowered by Evercore ISI from $20.00 to $15.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently ...

Fortrea Holdings Inc. (NASDAQ:FTRE – Get Free Report) shares gapped down before the market opened on Monday after the company announced weaker than expected quarterly earnings. The stock had ...

Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.18 per share, missing the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.19 per share a year ago.

Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be reporting earnings tomorrow before market hours. Here’s what ...

Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after the company delivered weak fourth-quarter 2024 results, with sales, operating profits ...